Adc Therapeutics Sa (ADCT)

$3.31 -0.02 (-0.60%)
Market Cap 363.37M
Revenue (ttm) 70.84M
Net Income (ttm) -157.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -222.83%
Debt to Equity Ratio -0.57
Volume 132,525
Avg Vol 660,778
Day's Range N/A - N/A
Shares Out 112.50M
Stochastic %K 53%
Beta 2.00
Analysts Strong Sell
Price Target $8.20

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 653 02 00
Address:
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland
Doozio
Doozio Sep. 5 at 3:45 PM
$ADCT it was always during 🐒🍌🧠⏰♾️
0 · Reply
SamHot
SamHot Sep. 5 at 3:44 PM
$ADCT Potential for TAKEOVER
0 · Reply
scalpemfast
scalpemfast Sep. 5 at 3:15 PM
$CRSP outflows in tech , looking for inflows $ADCT , $CRSP do you DD but its happening
0 · Reply
mhaven2020
mhaven2020 Sep. 5 at 2:09 PM
$MBOT $ADCT $HOTH bought early. caught a nice bump, closed some... this weeks alerts. Sign up and grab some before they pop! Check our website for details!
0 · Reply
scalpemfast
scalpemfast Sep. 5 at 3:13 AM
$CRSP ,$ADCT , heating up
0 · Reply
scalpemfast
scalpemfast Sep. 4 at 8:30 PM
$ADCT breaking out !!
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 30 at 3:43 PM
$RADX Lantheus CEO bullish on Radiopharm Theranostics.. company bought more ownership in first quarter. $PYXS $ADCT $IMNM
2 · Reply
scalpemfast
scalpemfast Aug. 28 at 2:04 PM
$ADCT looking good
0 · Reply
belugatrade
belugatrade Aug. 22 at 6:50 PM
$ADCT beauty!
0 · Reply
JRobb66
JRobb66 Aug. 22 at 8:34 AM
$ADCT what is the story here?? Nothing but good news and it falls below $3? C’mon now.. it’s a $10 stock all day..
0 · Reply
Latest News on ADCT
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Sep 2, 2025, 4:05 PM EDT - 9 days ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:15 AM EDT - 16 days ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 11:27 AM EDT - 4 weeks ago

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 12, 2025, 7:30 AM EDT - 4 weeks ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Aug 5, 2025, 4:05 PM EDT - 5 weeks ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:05 PM EDT - 2 months ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 16, 2025, 7:15 AM EDT - 3 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:45 AM EDT - 3 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

Jun 12, 2025, 6:30 AM EDT - 3 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 7:15 AM EDT - 4 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:36 PM EDT - 4 months ago

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 8:00 AM EDT - 4 months ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 14, 2025, 7:45 AM EDT - 4 months ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

May 8, 2025, 7:15 AM EDT - 4 months ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 28, 2025, 7:00 AM EDT - 4 months ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:15 AM EDT - 5 months ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 11:17 AM EDT - 6 months ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 27, 2025, 7:30 AM EDT - 6 months ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 5:30 PM EDT - 6 months ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

Mar 24, 2025, 11:08 PM EDT - 6 months ago

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Mar 20, 2025, 7:15 AM EDT - 6 months ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:15 AM EST - 8 months ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 30, 2024, 4:30 PM EST - 9 months ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

Dec 12, 2024, 2:03 PM EST - 9 months ago

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 11, 2024, 7:30 AM EST - 9 months ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 9, 2024, 7:30 AM EST - 9 months ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Dec 6, 2024, 7:30 AM EST - 10 months ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 11:01 AM EST - 10 months ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 8, 2024, 1:14 PM EST - 10 months ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 7, 2024, 7:30 AM EST - 11 months ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Nov 5, 2024, 9:47 AM EST - 11 months ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics to Present at November Investor Conferences

Nov 4, 2024, 7:15 AM EST - 11 months ago

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Oct 31, 2024, 7:15 AM EDT - 11 months ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 9:26 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jul 8, 2024, 2:00 AM EDT - 1 year ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

CG

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:04 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

May 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 6:10 AM EDT - 1 year ago

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

May 6, 2024, 6:00 AM EDT - 1 year ago

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

Apr 3, 2024, 7:00 AM EDT - 1 year ago

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19, 2024, 9:19 AM EDT - 1 year ago

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 1:24 PM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 13, 2024, 7:00 AM EDT - 1 year ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Doozio
Doozio Sep. 5 at 3:45 PM
$ADCT it was always during 🐒🍌🧠⏰♾️
0 · Reply
SamHot
SamHot Sep. 5 at 3:44 PM
$ADCT Potential for TAKEOVER
0 · Reply
scalpemfast
scalpemfast Sep. 5 at 3:15 PM
$CRSP outflows in tech , looking for inflows $ADCT , $CRSP do you DD but its happening
0 · Reply
mhaven2020
mhaven2020 Sep. 5 at 2:09 PM
$MBOT $ADCT $HOTH bought early. caught a nice bump, closed some... this weeks alerts. Sign up and grab some before they pop! Check our website for details!
0 · Reply
scalpemfast
scalpemfast Sep. 5 at 3:13 AM
$CRSP ,$ADCT , heating up
0 · Reply
scalpemfast
scalpemfast Sep. 4 at 8:30 PM
$ADCT breaking out !!
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 30 at 3:43 PM
$RADX Lantheus CEO bullish on Radiopharm Theranostics.. company bought more ownership in first quarter. $PYXS $ADCT $IMNM
2 · Reply
scalpemfast
scalpemfast Aug. 28 at 2:04 PM
$ADCT looking good
0 · Reply
belugatrade
belugatrade Aug. 22 at 6:50 PM
$ADCT beauty!
0 · Reply
JRobb66
JRobb66 Aug. 22 at 8:34 AM
$ADCT what is the story here?? Nothing but good news and it falls below $3? C’mon now.. it’s a $10 stock all day..
0 · Reply
fort_worth_Jason
fort_worth_Jason Aug. 19 at 7:01 PM
$ADCT- nothing but good news last week.
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:47 PM
Guggenheim has adjusted their stance on ADC Therapeutics ( $ADCT ), setting the rating to Buy with a target price of 10.
0 · Reply
d_risk
d_risk Aug. 13 at 5:41 AM
$ADCT - ADC Therapeutics SA Common Shares - 10Q - Updated Risk Factors ADCT flags new risks from potential tariff hikes raising costs and possible U.S. drug pricing policy shifts threatening product sales revenue. #Biotechnology #RegulatoryRisk #DrugPricing #TariffRisks #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/ADCT/10-Q/2025-08-12
0 · Reply
SirBensonNaija
SirBensonNaija Aug. 13 at 1:56 AM
$ADCT long
0 · Reply
JRobb66
JRobb66 Aug. 12 at 2:29 PM
$ADCT a whole lot of nothing So strange…
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 12 at 11:38 AM
$ADCT ADC Therapeutics Q2 Adj. EPS $(0.25) Beats $(0.39) Estimate, Sales $18.839M Beat $17.776M Estimate
1 · Reply
Dumont77
Dumont77 Aug. 11 at 4:07 PM
I like $ADCT as high risk play.
0 · Reply
christopher18
christopher18 Aug. 8 at 4:48 PM
$ADCT Predictions on Tuesday!
2 · Reply
hechicero1131
hechicero1131 Jul. 30 at 7:28 PM
$ADCT This sucks, huge green candles offset by major price drops on <5000 shares
0 · Reply
JRobb66
JRobb66 Jul. 29 at 2:57 PM
$ADCT maybe somebody knows something… too big of a sloooow drop
1 · Reply
fort_worth_Jason
fort_worth_Jason Jul. 24 at 4:41 PM
$ADCT Hoping for some good news soon.
0 · Reply
vjtweet
vjtweet Jul. 23 at 3:19 PM
$ADCT starter position.. to add more above 3.3
0 · Reply